Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of ACE910 (emicizumab) in healthy volunteers and hemophilia A patients
jRCT2080221889Phase 1
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2012
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of emicizumab in hemophilia A (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2080221889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221889.